TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology

Japan

TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology

Japan
SEARCH FILTERS
Time filter
Source Type

Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Himeno T.,Aichi Medical University | Kato Y.,Aichi Medical University | And 9 more authors.
Internal Medicine | Year: 2017

Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events, and its influence on the renal function. Results The patient’s mean glycated hemoglobin level significantly improved from 7.52±1.16% to 6.95± 0.98% (p<0.001). The body weight of the patients was significantly reduced from 78.0±15.3 kg to 75.6±15.1 kg (p<0.001). The estimated visceral fat area was also significantly reduced from 108.4±44.6 cm2 to 94.5± 45.3 cm2 (p<0.001). The waist circumference, blood pressure, serum alanine aminotransferase, γ-glutamyl transpeptidase, and uric acid levels also showed a significant decrease. The urinary albumin/creatinine ratio (U-ACR) was significantly reduced in the patients whose U-ACR levels were 30-300 mg/gCr at the baseline. The mean eGFR significantly decreased in the patients with a pre-treatment eGFR value of ≥90 mL/min/1.73 m2 but remained unchanged in the patients with a pre-treatment value of <90 mL/min/1.73 m2. A total of 13 adverse events were noted, including systemic eruption (n=1), cystitis (n=2), pudendal pruritus (n=2), nausea (n=1), malaise (n=1), a strong hunger sensation and increased food ingestion (n=1), and non-serious hypoglycemia (n=5). Conclusion SGLT2 inhibitors seemed to be useful in the treatment of obese type 2 diabetes mellitus patients. Furthermore, these data suggest that SGLT2 inhibitors may protect the renal function. © 2017 The Japanese Society of Internal Medicine.


Onoue T.,Nagoya University | Goto M.,Nagoya University | Kobayashi T.,Nagoya University | Tominaga T.,Nagoya University | And 8 more authors.
Nagoya Journal of Medical Science | Year: 2017

The Internet of Things (IoT) allows collecting vast amounts of health-relevant data such as daily activity, body weight (BW), and blood pressure (BP) automatically. The use of IoT devices to monitor diabetic patients has been studied, but could not evaluate IoT-dependent effects because health data were not measured in control groups. This multicenter, open-label, randomized, parallel group study will compare the impact of intensive health guidance using IoT and conventional medical guidance on glucose control. It will be conducted in outpatients with type 2 diabetes for a period of 6 months. IoT devices to measure amount of daily activity, BW, and BP will be provided to IoT group patients. Healthcare professionals (HCPs) will provide appropriate feedback according to the data. Non-IoT control, patients will be given measurement devices that do not have a feedback function. The primary outcome is glycated hemoglobin at 6 months. The study has already enrolled 101 patients, 50 in the IoT group and 51 in the non-IoT group, at the two participating outpatient clinics. The baseline characteristics of two groups did not differ, except for triglycerides. This will be the first randomized, controlled study to evaluate IoT-dependent effects of intensive feedback from HCPs. The results will validate a new method of health-data collection and provision of feedback suitable for diabetes support with increased effectiveness and low cost.


Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Kato Y.,Aichi Medical University | Kondo M.,Aichi Medical University | And 8 more authors.
Journal of the Japan Diabetes Society | Year: 2015

This study was conducted to investigate the efficacy and safety of a SGLT2 inhibitor, ipragliflozin, in Japanese patients with type 2 diabetes. Ipragliflozin was administered to a total of 89 out-patients treated with or without other oral hypoglycemic agents, insulin, or GLP-1 receptor agonists for 12 weeks. Significant decreases were observed in the HbA1c value from 7.46 ± 1.12 % to 7.02 ± 0.99 % (p<0.001), body weight from 76.4 ± 14.4 kg to 74.5 ± 14.2 kg (p<0.001), visceral fat mass from 100.4 ± 39.5 cm2 to 93.2 ± 33.7 cm2 (p= 0.011), systolic and diastolic blood pressure, waist circumference and the EGFR. As adverse events of ipragliflozin treatment, whole body eruption, cystitis and vaginal candidiasis in one case and non-severe hypoglycemia in 2 cases were observed. Ipragliflozin is relatively well-tolerated and effective for the treatment of Japanese obese patients with type 2 diabetes.

Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators
Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators